Monoclonal Anti-PNU-159682 Antibody, Rabbit IgG (M1E11)

Antibody Internalization Detection Reagent (IGG-PZF2001) monitors endocytosis in live cells
製品番号/仕様
価格
Availability
数量
PNU-MY2372-100ug
$315.00
In Stock - Delivery in 2-3 business days
PNU-MY2372-1mg (500ug X 2)
$1,890.00
In Stock - Delivery in 2 weeks
PNU-MY2372
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Chimeric Monoclonal Anti-PNU-159682 Antibody, Rabbit IgG (M1E11) is recombinantly expressed in HEK293. It consists of rabbit variable regions genetically fused to rabbit IgG constant domains.

Antibody Type

Recombinant Monoclonal

Clone

M1E11

Isotype

Rabbit IgG, Kappa

Host Species

Rabbit

Immunogen

PNU-BSA

Specificity

Specifically recognizes PNU.

Application
Application
Recommended Use / Performance
ELISA
0.2-2 μg/mL
Purification

Protein A purified.

Concentration

Please refer to the Certificate of Analysis (CoA).

Form

Lyophilized

Formulation

Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

Please contact us for customized product forms or formulations.

Reconstitution

Please refer to the Certificate of Analysis (CoA) for specific instructions.

Shipping

Lyophilized product is shipped at ambient temperature.

Storage

For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Notices

Product Specific Notices: For research use only.

バックグランド

PNU-159682 is a topoisomerase II inhibitor serving as a payload for antibody-drug conjugates (ADCs). Its mechanism of action involves stabilizing the complex formed by topoisomerase II and DNA, blocking DNA repair and replication processes, and thereby inducing cancer cell apoptosis. Some ADCs containing PNU-159682 have entered the preclinical research stage, showing targeted killing activity in solid tumor models, with particularly significant effects on tumors with high topoisomerase II expression.